A detailed history of Bank Of America Corp transactions in Vaxart, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 166,505 shares of VXRT stock, worth $96,572. This represents 0.0% of its overall portfolio holdings.

Number of Shares
166,505
Previous 166,236 0.16%
Holding current value
$96,572
Previous $111,000 27.03%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.58 - $0.99 $156 - $266
269 Added 0.16%
166,505 $141,000
Q2 2024

Aug 14, 2024

SELL
$0.53 - $1.3 $50,644 - $124,221
-95,555 Reduced 36.5%
166,236 $111,000
Q1 2024

May 15, 2024

BUY
$0.56 - $1.41 $48,037 - $120,952
85,782 Added 48.74%
261,791 $340,000
Q4 2023

Feb 14, 2024

SELL
$0.57 - $0.85 $16,272 - $24,265
-28,548 Reduced 13.96%
176,009 $100,000
Q2 2023

Aug 14, 2023

SELL
$0.6 - $1.41 $62,771 - $147,512
-104,619 Reduced 33.84%
204,557 $149,000
Q1 2023

May 12, 2023

BUY
$0.71 - $1.25 $154,092 - $271,290
217,032 Added 235.54%
309,176 $234,000
Q4 2022

Feb 10, 2023

SELL
$0.75 - $2.24 $636,876 - $1.9 Million
-849,169 Reduced 90.21%
92,144 $88,000
Q3 2022

Nov 14, 2022

BUY
$2.09 - $4.5 $1.47 Million - $3.17 Million
703,461 Added 295.76%
941,313 $2.05 Million
Q2 2022

Aug 12, 2022

SELL
$2.7 - $5.28 $1.06 Million - $2.08 Million
-394,009 Reduced 62.36%
237,852 $832,000
Q1 2022

May 16, 2022

BUY
$4.29 - $6.64 $604,173 - $935,131
140,833 Added 28.68%
631,861 $3.19 Million
Q4 2021

Feb 08, 2022

BUY
$5.77 - $7.96 $2.39 Million - $3.3 Million
414,297 Added 539.93%
491,028 $3.08 Million
Q3 2021

Nov 15, 2021

SELL
$6.67 - $9.8 $213,880 - $314,246
-32,066 Reduced 29.47%
76,731 $610,000
Q2 2021

Sep 13, 2021

BUY
$5.06 - $10.78 $550,512 - $1.17 Million
108,797 New
108,797 $815,000

Others Institutions Holding VXRT

About Vaxart, Inc.


  • Ticker VXRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,506,000
  • Market Cap $73.4M
  • Description
  • Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...
More about VXRT
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.